Antiglycation and antioxidant effect of carnosine against glucose degradation products in peritoneal mesothelial cells.
OBJECTIVE
Toxicity with advanced glycation end products (AGEs) is a major problem in uremic patients. Treatment with peritoneal dialysis (PD) exacerbates AGE formation as a result of bioincompatibility of the conventional peritoneal dialysis fluid (PDF). The presence of glucose degradation products (GDPs) in PDF is the main cause of its bioincompatibility. Carnosine is an endogenous dipeptide with a powerful antiglycation/antioxidant activity. In an attempt to improve PDF biocompatibility, we evaluated the effect of carnosine in human peritoneal mesothelial cells (HPMC) incubated with PDF or GDPs in vitro.


METHODS
HPMC were incubated for short or prolonged time with PDF in the presence or absence of carnosine. Similarly, HPMC were incubated in the same condition but with a combination of GDPs. Following the incubation, cells were tested for their viability, protein carbonyl content and reactive oxygen species (ROS) production.


RESULTS
Results demonstrated a significant protective effect of carnosine to HPMC in both acute and chronic conditions with PDF or GDPs as judged by the enhancement of cell viability, preserved protein from modification and decreased ROS production.


CONCLUSIONS
Carnosine enhanced HPMC viability against the toxic effect of GDPs probably through protection of cellular protein from modification and from ROS-mediated oxidative damage. The salutary effect of carnosine may render it a desirable candidate for improving PDF biocompatibility and reducing AGE complications in PD patients.
Alhamdani
Mohamed-Saiel Saeed
MS
Department of Medical Sciences, College of Pharmacy, Al-Mustansiriya University Baghdad, Iraq. ms.alhamdani@gmail.com
Al-Kassir
Abdul-Hameed A-M
AH
Abbas
Fawzi K H
FK
Jaleel
Nidham A
NA
Al-Taee
Maha F
MF
D000975:Antioxidants / Q000494:pharmacology*; D002336:Carnosine / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D010529:Peritoneal Cavity / Q000166:cytology / Q000502:physiology*
D000975:Antioxidants; D017127:Glycation End Products, Advanced; D002336:Carnosine; D005947:Glucose